Olmesartanmedoxomil/ Hydrochloorthiazide Sandoz (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxil / Hydrochlorothiazide is an antihypertensive medication that acts on the renin‑angiotensin system and renal sodium handling.

• Primary (essential) hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk.
• Secondary hypertension: provides effective blood pressure control when hypertension is due to identifiable causes.
• Hypertension with fluid retention: combines vasodilation with diuresis to manage elevated blood pressure and excess extracellular fluid.

• Olmesartan medoxil selectively blocks AT1 receptors, preventing angiotensin II‑mediated vasoconstriction and aldosterone release. Hydrochlorothiazide inhibits Na+/Cl‑ reabsorption in the distal convoluted tubule, promoting natriuresis and diuresis, which together reduce peripheral vascular resistance and blood volume, leading to lowered arterial pressure.

Common Side Effects

• Dizziness: transient light‑headedness, especially after the first dose.
• Headache: mild to moderate intensity.
• Fatigue: feeling of tiredness or reduced energy.
• Increased urination: due to the diuretic component.
• Electrolyte imbalance: mild changes in potassium or sodium levels.
• Mild gastrointestinal discomfort: occasional nausea or abdominal pain.

Serious or Rare Side Effects

• Severe dehydration: marked fluid loss requiring medical attention.
• Acute kidney injury: sudden decline in renal function.
• Hyperkalemia: dangerously high potassium levels, especially with other potassium‑sparing agents.
• Allergic reactions: rash, itching, or hives.
• Angioedema: swelling of face, lips, tongue, or throat.
• Severe electrolyte disturbances: significant hyponatremia or hypokalemia.

Patients should be monitored for blood pressure response and renal function while on therapy.

• Blood pressure monitoring: ensure target levels are achieved without excessive hypotension.
• Renal function assessment: check serum creatinine and eGFR before and during treatment.
• Electrolyte surveillance: periodic measurement of potassium and sodium.
• Pregnancy caution: contraindicated in pregnancy (Category D) due to fetal risk.
• Concomitant drug review: avoid combining with other potent diuretics or potassium‑sparing agents without supervision.
• Store at room temperature below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Olmesartan medoxil / Hydrochlorothiazide may interact with several drug classes.

Major Interactions (Avoid)

• Aliskiren: combined use can increase risk of renal impairment and hyperkalemia.
• Lithium: thiazide component may raise lithium levels, leading to toxicity.
• NSAIDs: may blunt antihypertensive effect and affect renal function.
• ACE inhibitors or other ARBs: concurrent use raises risk of hyperkalemia and renal dysfunction.
• Potassium‑sparing diuretics: increase risk of hyperkalemia.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: additive blood pressure lowering effect.
• Calcium channel blockers: may enhance antihypertensive response.
• Antidiabetic agents: diuretic may affect glucose control.
• Antidepressants (SSRIs): potential for increased serum sodium loss.
• Antimicrobials (e.g., ciprofloxacin): may affect renal clearance of the ARB.